APA (7th ed.) Citation

G, V., T, P., P, T., J, C., J, P., A, L., . . . SM, T. (2025). HER2DX and survival outcomes in early-stage HER2-positive breast cancer: An individual patient-level meta-analysis. The Lancet. Oncology, 26(8), 1100. https://doi.org/10.1016/S1470-2045(25)00276-1

Chicago Style (17th ed.) Citation

G, Villacampa, et al. "HER2DX and Survival Outcomes in Early-stage HER2-positive Breast Cancer: An Individual Patient-level Meta-analysis." The Lancet. Oncology 26, no. 8 (2025): 1100. https://doi.org/10.1016/S1470-2045(25)00276-1.

MLA (9th ed.) Citation

G, Villacampa, et al. "HER2DX and Survival Outcomes in Early-stage HER2-positive Breast Cancer: An Individual Patient-level Meta-analysis." The Lancet. Oncology, vol. 26, no. 8, 2025, p. 1100, https://doi.org/10.1016/S1470-2045(25)00276-1.